There has been a lucrative turnover in business by emphasizing on the key strategic elements (KSE) i.e, yielding premium growth, directing better production, aiding persistency and reducing claims. Indirectly proportional COVID-19 fatalities to augmented vaccinations lead to positive outlook. Hence, we reiterate our BUY rating on the stock with a rolled forward TP of Rs. 657 based on 2.0x FY24E EVPS. Premium growth led by well diversified product and distribution mix In Q3FY22, gross premium and net premium stood flat at Rs. 9,344cr (+2.1% YoY) and...